Sonnet Biotherapeutics Holdings

Sonnet BioTherapeutics is a clinical-stage biotechnology company developing engineered biologic medicines based on its Fully Human Albumin-Binding, or FHAB, platform. The company uses single-chain antibody fragments that bind human albumin to extend half-life and improve biodistribution of immune-modulating payloads, particularly cytokines and other biologic effectors. Its pipeline has focused on oncology programs including FHAB-fused interleukin-12 and interleukin-18 candidates, as well as earlier immuno-oncology constructs directed at CD40 and BCMA. Sonnet is publicly traded and positions its platform as a way to improve the therapeutic index of potent immune agents that have historically been limited by toxicity and pharmacokinetics.